| Fund ID | 805-7795200121 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | No |
| Annual audit | No |
| Prepared per GAAP | No |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 100% |
| Owned by funds of funds | 86% |
| Owned by non-U.S. persons | 86% |
| Fund | Type | Gross assets |
|---|---|---|
| Novaquest Pharma Opportunities Fund V, L.P. | Private Equity | $630.8M |
| Novaquest Pharma Opportunities Fund V (delaware), L.P. | Private Equity | $386.7M |
| Novaquest Pharma Opportunities Fund IV, L.P. | Private Equity | $158.1M |
Nq Ah Project Arlington II, L.P. reports $21.3 million in gross assets, among the top 68% of private funds by size.
The stated minimum investment is $5 million.
Nq Ah Project Arlington II, L.P. is managed by Novaquest Capital Management, L.L.C.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.